Systemic Agents for Severe Atopic Dermatitis in Children (Q38627693)

4 September 2017

Systemic Agents for Severe Atopic Dermatitis in Children (English)

1 reference

4 September 2017

1 reference

Eliza R Notaro

1

1 reference

PubMed ID

26547214

4 September 2017

Robert Sidbury

series ordinal

2

1 reference

4 September 2017

7 November 2015

1 reference

4 September 2017

1 reference

4 September 2017

17

1 reference

4 September 2017

6

1 reference

4 September 2017

449-457

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-015-0150-4

4 September 2017

0 references

cites work

New insights into the epidemiology of childhood atopic dermatitis

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

The prevalence of childhood atopic eczema in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Update on systemic therapies for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Factors determining the effectiveness of oral ciclosporin in the treatment of severe childhood atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

A randomized trial of methotrexate versus azathioprine for severe atopic eczema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Efficacy and safety of treatments for childhood psoriasis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Methotrexate for treatment of atopic dermatitis in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Anti-immunoglobulin E in the treatment of refractory atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Polydesensitisation with reducing elevated serum total IgE by IFN-gamma therapy in atopic dermatitis: IFN-gamma and polydesensitisation (PDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Recombinant interferon gamma therapy for atopic dermatitis

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

21 January 2018

12 December 2020

Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Dyshidrotic eczema following intravenous immunoglobulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Vitamin D Status and Its Association with the SCORAD Score and Serum LL-37 Level in Korean Adults and Children with Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Sévérité de la dermatite atopique et taux de vitamine D : étude transversale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Low vitamin D serum level is inversely associated with eczema in children and adolescents in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Low vitamin D levels are associated with atopic dermatitis, but not allergic rhinitis, asthma, or IgE sensitization, in the adult Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Vitamin D level in children is correlated with severity of atopic dermatitis but only in patients with allergic sensitizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Cord blood 25(OH)-vitamin D deficiency and childhood asthma, allergy and eczema: the COPSAC2000 birth cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Vitamin D concentration in newborn cord blood is correlated with maternal intake of supplemental vitamin D, and lower levels are associated with increased risk of the infant developing eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Delayed acyclovir and outcomes of children hospitalized with eczema herpeticum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Antihistamines in the pediatric population: achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-015-0150-4

Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis

21 January 2018

1 reference

12 December 2020

Cord Blood 25-Hydroxyvitamin D3 and Allergic Disease During Infancy

1 reference

12 December 2020

Experience with intravenous immunoglobulin in severe childhood atopic dermatitis

1 reference

12 December 2020

Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial

1 reference

12 December 2020

Seasonal allergic rhinitis and antihistamine effects on children's learning.

1 reference

12 December 2020

The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma

1 reference

12 December 2020

Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis

1 reference

12 December 2020

Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma

1 reference

12 December 2020

Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema

1 reference

12 December 2020

A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life

1 reference

12 December 2020

Vitamin D supplementation in the treatment of atopic dermatitis: a clinical trial study

1 reference

12 December 2020

Vitamin D deficiency is associated with diagnosis and severity of childhood atopic dermatitis

1 reference

12 December 2020

Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

12 December 2020

Serum Vitamin D levels and Vitamin D supplementation do not correlate with the severity of chronic eczema in children.

1 reference

12 December 2020

Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial

1 reference

12 December 2020

Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study

1 reference

12 December 2020

A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis

1 reference

12 December 2020

Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases

1 reference

12 December 2020

A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis

1 reference

12 December 2020

Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis

1 reference

12 December 2020

Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series

1 reference

12 December 2020

Association between copy-number variations of the human histamine H4 receptor gene and atopic dermatitis in a Chinese population.

1 reference

12 December 2020

Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients

1 reference

12 December 2020

Vitamin D Supplementation Modulates the Immune System and Improves Atopic Dermatitis in Children

1 reference

12 December 2020

Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant

1 reference

12 December 2020

10.1007/S40272-015-0150-4

Identifiers

DOI

1 reference

PubMed ID

26547214

Dimensions Publication ID

4 September 2017

0 references

1 reference

PubMed ID

26547214